Omada Health (NASDAQ:OMDA) CEO Sells 14,158 Shares of Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 14,158 shares of the company’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $20.00, for a total transaction of $283,160.00. Following the completion of the transaction, the chief executive officer owned 394,603 shares of the company’s stock, valued at approximately $7,892,060. This trade represents a 3.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Omada Health Stock Performance

Shares of OMDA traded up $1.99 during mid-day trading on Friday, reaching $20.89. 3,310,497 shares of the company’s stock traded hands, compared to its average volume of 946,807. The business’s 50-day moving average price is $16.51 and its 200-day moving average price is $14.85. Omada Health, Inc. has a 12 month low of $10.28 and a 12 month high of $26.92.

Omada Health (NASDAQ:OMDA) last posted its earnings results on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.03. The firm had revenue of $78.05 million for the quarter. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%. On average, analysts predict that Omada Health, Inc. will post -0.01 earnings per share for the current year.

Analysts Set New Price Targets

OMDA has been the topic of several recent analyst reports. Canaccord Genuity Group set a $24.00 target price on Omada Health in a report on Friday, May 8th. Barclays lifted their price target on Omada Health from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Omada Health in a report on Thursday, June 4th. Wall Street Zen cut Omada Health from a “buy” rating to a “hold” rating in a research note on Saturday, May 30th. Finally, Evercore reiterated an “outperform” rating and issued a $20.00 price target on shares of Omada Health in a research report on Friday, May 8th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $22.91.

Institutional Investors Weigh In On Omada Health

Hedge funds have recently modified their holdings of the stock. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Omada Health in the fourth quarter worth $1,222,000. Divisadero Street Capital Management LP acquired a new stake in Omada Health during the 3rd quarter worth about $30,510,000. a16z Perennial Management L.P. purchased a new position in Omada Health during the 4th quarter valued at about $2,480,000. Madryn Asset Management LP acquired a new position in shares of Omada Health in the 4th quarter valued at about $9,212,000. Finally, Independent Advisor Alliance acquired a new position in shares of Omada Health in the 4th quarter valued at about $717,000.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.